Structure Therapeutics In... (GPCR)
Structure Therapeutics Inc. (GPCR) Stock Price, Analysis & Data
| Bid | 36.54 |
| Market Cap | 3.83B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -214.84M |
| Beta | n/a |
| EPS (ttm) | -3.03 |
| PE Ratio (ttm) | n/a |
| Forward PE | -25.49 |
| P/B (ttm) | 2.52 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 64 |
| Volume | 1,472,647 |
| Avg. Volume (20D) | 703,751 |
| Open | 52.55 |
| Previous Close | 52.13 |
| Day's Range | 51.06 - 53.92 |
| 52-Week Range | 18.26 - 94.90 |
| Analyst | Strong Buy |
| Price Target | 104 (92.91%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. Th...
Financial Performance
In 2025, Structure Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -141.2M, an increase of 15.24%.
Financial StatementsAnalyst Forecast
According to 15 analyst ratings, the average rating for GPCR stock is "Strong Buy". The 12-month stock price forecast is 104, which is upside of 92.91% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
